Lith-O-Asp
Based on 4 publication(s) in Google Scholar
Lith-O-Asp is a sialytransferase (ST) inhibitor, with IC50s of 12-37 μM.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 881179-02-8
- Formula: C28H45NO6
- Molecular Weight:491.66
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Lith-O-Asp
More
Biological Activity
IC50: 12-37 μM (ST)[1].
The results indicate that Lith-O-Asp shows no apparent growth inhibition effect toward different cancer cell lines at the tested doses of 10, 30, and 60 μM. By in vitro activity assay, it is revealed that the ability of Lith-O-Asp to inhibit the activities of ST3Gal I, ST3Gal III, and ST6GalI. The IC50 values ranged from 12 to 37 μM. Flow cytometry shows a significant decrease in the expression of cell surface a-2,3- and a-2,6-sialylated antigens on The results indicates that Lith-O-Asp decreased the activity of both a-2,3- and a-2,6-sialyltransferases, and thus inhibit the transfer of sialic acids to the targeted glycoproteins[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 881179-02-8
-
Appearance Solid
-
Molecular Weight 491.66
-
Formula C28H45NO6
-
Color White to off-white
-
SMILES
C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(O)=O)([H])[C@@]3([H])[C@]([C@@]4([C@](C[C@H](OC([C@@H](N)CC(O)=O)=O)CC4)([H])CC3)C)([H])CC1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Nature
2022 May;605(7911):747-753. PMID: 35585241 -
Cancer Discov
Mismatch Repair-Proficient Colorectal Cancer can evade Immune Surveillance Through an Intrinsic Suppressive Program. [Abstract]2026 May 13. PMID: 42126206 -
Redox Biol
Supplementing sialic acid analogs overcomes radiotherapy resistance in triple-negative breast cancer by exacerbating ER stress. [Abstract]2025 Jun 7:85:103712. PMID: 40505348 -
Cell Rep
Goblet cell-expressed microprotein FXYD3 determines gut homeostasis by maintaining mucus barrier integrity. [Abstract]2025 Nov 25;44(11):116502. PMID: 41187059
Solvent & Solubility
DMSO : 100 mg/mL (203.39 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.08 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.08 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
About 3x104 of the CL1-0, CL1-5, A549, and H1299 lung cancer cells are seeded on 12-well culture dishes in DMEM containing 10% FBS. Different concentrations of Lith-O-Asp (10, 30, and 60 μM) are added into each plate and incubated for 48 hr. Cell viabilities under different concentrations of compound treatment are determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. In the untreated control, 0.1% DMSO-containing medium is used[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[1]
The BALB/c mice are used. Highly metastatic murine 4T1-Luc breast cancer cells (5 x105) are subcutaneously injected into the mammary fat pad of mice. Mice receive 3 mg/kg of Lith-O-Asp intraperitoneally on every other day. DMSO treatment is used as control. The growth and the spontaneous metastasis of the tumors are observed under IVIS50 in vivo imaging system with endotoxin-free luciferase substrate injection. The metastasized tumor tissues are dissected on day 26[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0339 mL | 10.1696 mL | 20.3393 mL | 50.8481 mL |
| 5 mM | 0.4068 mL | 2.0339 mL | 4.0679 mL | 10.1696 mL | |
| 10 mM | 0.2034 mL | 1.0170 mL | 2.0339 mL | 5.0848 mL | |
| 15 mM | 0.1356 mL | 0.6780 mL | 1.3560 mL | 3.3899 mL | |
| 20 mM | 0.1017 mL | 0.5085 mL | 1.0170 mL | 2.5424 mL | |
| 25 mM | 0.0814 mL | 0.4068 mL | 0.8136 mL | 2.0339 mL | |
| 30 mM | 0.0678 mL | 0.3390 mL | 0.6780 mL | 1.6949 mL | |
| 40 mM | 0.0508 mL | 0.2542 mL | 0.5085 mL | 1.2712 mL | |
| 50 mM | 0.0407 mL | 0.2034 mL | 0.4068 mL | 1.0170 mL | |
| 60 mM | 0.0339 mL | 0.1695 mL | 0.3390 mL | 0.8475 mL | |
| 80 mM | 0.0254 mL | 0.1271 mL | 0.2542 mL | 0.6356 mL | |
| 100 mM | 0.0203 mL | 0.1017 mL | 0.2034 mL | 0.5085 mL |